Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2022 | Immune gene signatures predict CPR of NSCLC treated with neoadjuvant chemoimmunotherapy

Marta Casarrubios, MSc, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain, talks on an analysis into pre-treatment tumor samples of patients from the Phase II NADIM (NCT03081689) trial undergoing neoadjuvant chemoimmunotherapy. A pro-inflammatory tumor profile in patients with complete pathological response (CPR) was found, dominated by a higher proportion of M1 macrophages. Additionally patients with CPR had a higher expression of pathways associated with lymphocyte infiltrate and antigen presentation. Together, these finding suggest the immune system of patients with CPR was activated prior to immunotherapy compared to non-complete pathological responders. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.